Navigation Links
US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
Date:9/24/2007

to late disease diagnosis, currently only about 25% of patients are eligible for surgery and half of those patients will have their disease recur within 12-15 months. No products have been approved by the FDA to prolong the time a patient remains disease free following surgery.

The fast track designation is fully aligned with Progen's Phase 3 trial design. The double blinded, placebo-controlled Phase 3 trial will be powered for the primary endpoint of disease-free survival determining if PI-88 can prevent early recurrence following curative hepatic surgery. The trial will begin later this year and targets 600 patients with liver cancer post resection, in more than a dozen countries.

About Progen:

Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

About PI-88:

PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes - angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) - critical to the growth and progression of cancer. In a Phase 2 trial in post-resection liver cancer, PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

Progen Information:

Justus Homburg

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Noreen Dillane<
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Stop HIV/AIDS in its Tracks with Education
2. Team Tracks Genetic Origins of Eye Cancer
3. Sex-change Only on Paper? Health Watch Dog Backtracks on Proposal
4. CDC Study Tracks Levels of Heart Diseases Across the U.S.
5. New Imaging Technique Tracks Traffic Patterns of White Blood Cells
6. Allergy Alert on Undeclared Peanuts in Mayfield Turtle Tracks Ice Cream
7. Advances in Treatment of Cataracts
8. Recommendations for Treatment of Blood Pressue
9. Thyroid hormone treatment hastens recovery after cardiac surgery
10. Feeding channel created by malaria parasite - a new target for malaria treatments
11. Now umbilical cord helps in stroke treatment.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... review of clinical trials based on administering antidepressants ... concluded that more trials are needed to determine ... pain on a regular basis., Dr. Ian Gilron, ... in the Department of Anesthesiology, and his team ... whether the use of antidepressants for pain relief ...
(Date:8/29/2014)... by the Mental Health Commission of Canada identifies ... education that police personnel receive. , "People with ... police community, and today,s report builds on the ... with mental illnesses," says Queen,s adjunct professor Dorothy ... the area of police psychology. "This is a ...
(Date:8/29/2014)... US Preventive Services Task Force recommendations for screening and ... may be ameliorated through technological approaches according to a ... published online August 21, 2014 in the Journal ... David Levine, MD, MA, a third year resident in ... colleagues found that compared to usual care, technology-assisted interventions ...
(Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
(Date:8/29/2014)... 29, 2014 A team of experts ... is on its way to the 2014 National Safety ... Convention Center to exhibit and demonstrate a suite of ... industrial environments. Etymotic’s safety earphones and high-definition earplugs are ... at the show. , The company’s HD5 high-definition, ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Report advocates improved police training 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... Operating Cash Flow of $173 Million, and Generates $98 ... to Reflect Year-to-Date Sales Results, Maintains Bottom-Line GuidanceAUSTIN, Texas, ... WFMI ) today reported results for the 12-week ... the quarter were $1.9 billion, in line with the ...
... clinical trial led by Dr. Katherine Borden, at the ... the Universit de Montral, has shown that a common ... of cancer patients. Published in the journal Blood ... the activities of the eIF4E gene in patients. This ...
... American Pathologists today joined a lawsuit against the U.S. Patent and ... for the genes known as BRCA1 and BRCA2, which are indicators ... ... Washington, D.C. (Vocus) May 13, 2009 -- The College of ...
... the findings of a landmark drug comparison study published in ... other medications for high blood pressure. A scientific team including ... Houston reports the findings in the May 11 issue of ... in three adults in the United States has high blood ...
... be the newest "Biggest Loser" but she is a real ... is about simple, everyday choices that can help you be ... the glass and is one of the simplest things you ... and athletes to don a ,stache for the National Milk ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
Cached Medicine News:Health News:Whole Foods Market Reports Second Quarter 2009 Results 2Health News:Whole Foods Market Reports Second Quarter 2009 Results 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 4Health News:Whole Foods Market Reports Second Quarter 2009 Results 5Health News:Whole Foods Market Reports Second Quarter 2009 Results 6Health News:Whole Foods Market Reports Second Quarter 2009 Results 7Health News:Whole Foods Market Reports Second Quarter 2009 Results 8Health News:Whole Foods Market Reports Second Quarter 2009 Results 9Health News:Whole Foods Market Reports Second Quarter 2009 Results 10Health News:Whole Foods Market Reports Second Quarter 2009 Results 11Health News:Whole Foods Market Reports Second Quarter 2009 Results 12Health News:Whole Foods Market Reports Second Quarter 2009 Results 13Health News:Whole Foods Market Reports Second Quarter 2009 Results 14Health News:Whole Foods Market Reports Second Quarter 2009 Results 15Health News:Whole Foods Market Reports Second Quarter 2009 Results 16Health News:Whole Foods Market Reports Second Quarter 2009 Results 17Health News:Whole Foods Market Reports Second Quarter 2009 Results 18Health News:Whole Foods Market Reports Second Quarter 2009 Results 19Health News:Whole Foods Market Reports Second Quarter 2009 Results 20Health News:Whole Foods Market Reports Second Quarter 2009 Results 21Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
(Date:8/29/2014)...  BC Technical, the nation,s leading non-OEM provider of ... leader in sales, service and installation of GE MRI ... to continue to expand their resources and inventory while ... "We are committed to driving higher ... president and CEO of BC Technical. "We set out ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
... 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, ... European Time members of Cell Therapeutics, Inc.'s ... to discuss today's,announcement of the interim results ... to CPOP-R, in which pixantrone is substituted ...
... in a physicians office practice, can be instrumental ... ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular ... for urinalysis tests is well in excess of ... For such a fundamental, extensive and economically significant ...
Cached Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Urinalysis Analyzers: Large Capabilities in Every Size Device 2Urinalysis Analyzers: Large Capabilities in Every Size Device 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: